Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-23T21:02:00.847Z Has data issue: false hasContentIssue false

P0266 - Metabolic side effects of atypical antipsychotics in early onset schizophrenia: One year follow-up pilot study

Published online by Cambridge University Press:  16 April 2020

J.L. Goeb
Affiliation:
Department of Child and Adolescent Psychiatry, University Hospital Centre of Lille, Lille, France
S. Marco
Affiliation:
Department of Child and Adolescent Psychiatry, University Hospital Centre of Lille, Lille, France
A. Duhamel
Affiliation:
Department of Biostatistics, CERIM, University of Lille, Lille, France
R. Jardri
Affiliation:
Department of Child and Adolescent Psychiatry, University Hospital Centre of Lille, Lille, France
G. Kechid
Affiliation:
Department of Child and Adolescent Psychiatry, University Hospital Centre of Lille, Lille, France
R. Bordet
Affiliation:
Department of Pharmacology, University of Lille, Lille, France
P. Delion
Affiliation:
Department of Child and Adolescent Psychiatry, University Hospital Centre of Lille, Lille, France
P. Thomas
Affiliation:
Department of General Psychiatry, University Hospital Centre, Lille, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To assess weight gain in adolescents treated with antipsychotic drugs for early onset schizophrenia (EOS).

Method:

One-year follow-up of 13 consecutive adolescents (10 male, 3 females, age range: 11-16) treated with atypical antipsychotics for early onset schizophrenia (according to DSM-IV criterias). The main outcome measure is sex- and age-adjusted Z scores of Body Mass Index (BMI).

Results:

BMI, sex- and age-adjusted BMI percentiles and BMI Z scores are significantly increased in schizophrenic adolescents after prescription of atypical antipsychotics (p= 0.025).

Conclusions:

Despite the limited number of children included, this pilot study confirms a significant link between prescription of risperidone in early onset schizophrenia and increase of adjusted BMIZ scores. Clinicians and caregivers are to be aware of potential metabolic adverse effects of these medications. These findings suggest a regular health monitoring in adolescents treated with atypical antipsychotics, before and along the prescription.

Type
Poster Session I: Neuroleptics and Antipsychotics
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.